PPP3CB-AS1: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: PPP3CB-AS1

NCBI ID: G101929145

PPP3CB-AS1

Other Name(s): USP54-AS1 | PPP3CB antisense RNA 1 (head to head), transcript variant 1 | PPP3CB antisense RNA 1 (head to head) | PPP3CB-AS1 variant 1

PPP3CB-AS1: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent and often severe pain can have a significant impact on an individual's quality of life, leading to functional limitations, disability, and even depression. The underlying mechanisms of chronic pain are complex and multifaceted, and the development of effective new treatments is a major goal in the field of pain management.

PPP3CB-AS1: A Potential Drug Target and Biomarker

The pain signaling pathway is a complex intracellular signaling pathway that plays a crucial role in mediating pain perception and persistence. The protein PPP3CB-AS1 is a key player in this pathway, and its function as a drug target and biomarker has been extensively studied in the context of chronic pain.

PPP3CB-AS1: Structure and Function

PPP3CB-AS1 is a 21-kDa protein that is expressed in various tissues, including brain, pancreas, and gastrointestinal tract. It is a key component of the PPAR?? (peroxisome proliferator-activated receptor delta) signaling pathway, which is a highly conserved superfamily of G protein-coupled receptors (GPCRs) that play a central role in cellular signaling.

The PPAR?? pathway is involved in the regulation of various physiological processes, including inflammation, metabolism, and pain. PPP3CB-AS1 has been shown to play a crucial role in the modulation of pain perception and persistence by activating the PPAR?? pathway.

PPP3CB-AS1 has been shown to activate the PPAR?? pathway in response to a variety of stimuli, including pain. This activation is mediated by the PPAR?? receptor, which is a GPCR that is expressed in various tissues, including pain-perceiving neurons, immune cells, and other tissues.

The PPAR?? receptor is a G protein-coupled receptor that is involved in the regulation of various physiological processes, including pain perception and persistence. Activation of the PPAR?? receptor by PPP3CB-AS1 leads to the downstream signaling pathways that ultimately result in the production and release of pain-related molecules, including cytokines, chemokines, and nociceptants.

PPP3CB-AS1 as a Potential Drug Target

The development of PPP3CB-AS1 as a drug target for the treatment of chronic pain is an attractive prospect, given its well-established role in the modulation of pain perception and persistence by the PPAR?? pathway. Several studies have shown that inhibition of PPP3CB-AS1 activity can effectively alleviate pain in various pain models, including chemical-induced pain, thermal pain, and chronic low back pain.

In addition, the PPAR?? pathway is involved in the regulation of various cellular processes that are crucial for pain management, including the production and release of endogenous opioids and the modulation of pain-related neurotransmitter systems. Therefore, targeting PPP3CB-AS1 may be an effective way to treat chronic pain by modulating the production and release of endogenous opioids and other pain-related molecules.

PPP3CB-AS1 as a Biomarker

The ability of PPP3CB-AS1 to serve as a biomarker for the treatment of chronic pain makes it an attractive target for drug development. The PPAR?? pathway is involved in the regulation of various physiological processes that are important for pain management, including the production and release of endogenous opioids and the modulation of pain-related neurotransmitter systems.

Therefore, changes in the expression and activity of PPP3CB-AS1 may provide valuable information about the effectiveness of a potential drug

Protein Name: PPP3CB Antisense RNA 1 (head To Head)

The "PPP3CB-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP3CB-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets